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Tenofovir, combined with emtricitabine or lamivudine, was intro­
duced to the South African (SA) antiretroviral therapy (ART) 
guidelines in 2010 as the preferred nucleoside reverse transcriptase 
inhibitor (NRTI) for HIV­infected patients starting first­line 
ART. Tenofovir is associated with kidney toxicity,[1] and estimated 
probabilities of tenofovir discontinuation as a result of kidney 
toxicity in cohort studies (with durations of follow­up longer than 
a year) range from 2.3% to 9.2%.[2­6] Impairment of kidney function 
at baseline is an important risk factor for the development of kidney 
toxicity on tenofovir.[7]
While several guidelines recommend excluding kidney disease 
before starting tenofovir, and monitoring kidney function while on 
treatment so that tenofovir can be stopped should toxicity develop, 
some authors argue that tenofovir can be used safely without 
monitoring.[1,8,9] There is also evidence that clinicians do not always 
follow monitoring guidelines, even when laboratory monitoring is 
available.[7,20] The SA 2010 ART guidelines recommended measure­
ment of the serum creatinine concentration before treatment 
initiation, at 3, 6 and 12 months after initiation and then annually, 
with calculation of creatinine clearance (CrCl) using the Cockcroft­
Gault formula. Tenofovir was contraindicated in patients with a 
CrCl <50 mL/min. We used retrospective cohort data from two 
urban SA ART sites to describe clinician compliance with tenofovir 
prescribing and monitoring guidelines in HIV­infected adults on 
first­line ART.
Methods
We included treatment­naive patients aged ≥16 years who started 
first­line tenofovir­based ART between 2010 and 2012 at Khayelitsha 
and Themba Lethu clinics in Cape Town and Johannesburg, SA, 
respectively. Both are public sector HIV clinics that manage patients 
according to standard national ART protocols.[11,12]
We calculated the proportions of patients who had creatinine 
concentration recorded at baseline (between 6 months before and 2 
weeks after treatment initiation) and at 3 months (0.5 ­ 4 months), 6 
months (4 ­ 8 months) and 12 months (8 ­ 18 months) after treatment 
initiation. We calculated CrCl using the Cockcroft­Gault formula: 
CCr (mL/min) = [(140 – age) × weight (kg)] (× 0.85 if female)/SCr 
(μmol/L).[13] Patient weights were not always available on the same 
date as creatinine concentrations. For baseline CrCls we matched the 
closest weight to each creatinine concentration if both were within 
the baseline window, and they were within 30 days of each other. 
From 2 weeks to 6 months after treatment initiation we matched the 
closest weight to each creatinine concentration if they were within 
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Background. Tenofovir is part of the preferred first­line regimen for HIV­infected patients in South Africa (SA), but is associated with 
kidney toxicity. SA antiretroviral therapy (ART) guidelines recommend creatinine monitoring at baseline (ART start) and at 3, 6 and 12 
months, and substituting tenofovir with zidovudine, stavudine or abacavir should creatinine clearance (CrCl) decrease to <50 mL/min.
Objective. To assess clinician compliance with tenofovir monitoring and prescribing guidelines.
Methods. We described the proportion of adult patients on tenofovir­based first­line ART who were screened for baseline renal impairment, 
were monitored according to the SA antiretroviral treatment guidelines, and were switched from tenofovir if renal function declined.
Results. We included 13 168 patients who started ART from 2010 to 2012. Creatinine concentrations were recorded in 11 712 (88.9%) 
patients on tenofovir at baseline, 9 135/11 657 (78.4%) at 3 months, 5 426/10 554 (51.4%) at 6 months, and 5 949/ 8 421 (70.6%) at 12 
months. At baseline, 227 (1.9%) started tenofovir despite a CrCl <50  mL/min. While on tenofovir, 525 patients had at least one CrCl 
of <50 mL/min. Of 382 patients with ≥3 months’ follow­up after a CrCl <50 mL/min, 114 (29.8%) stopped tenofovir within 3 months. 
Clinicians were more likely to stop tenofovir in patients with lower CrCl and CD4 count. Of 226 patients who continued to receive tenofovir 
and had further CrCls available, 156 (69.0%) had a CrCl ≥50 mL/min at their next visit.
Conclusions. Creatinine monitoring is feasible where access to laboratory services is good. Kidney function recovered in most patients who 
continued to receive tenofovir despite a CrCl <50 mL/min. Further research is needed to determine how best to monitor renal function 
with tenofovir in resource­limited settings.
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14 days of each other. After 6 months we carried weights forward for 
up to 9 months if weights were missing. We calculated the proportion 
of patients who stopped tenofovir within 3 months of a CrCl <50 mL/
min, either at baseline or while on treatment (excluding those who 
switched to second­line regimens because of virological failure). 
We defined time on tenofovir as the time from treatment initiation 
until stopping tenofovir or the end of follow­up. Multivariate logistic 
regression analysis was used to identify factors associated with 
stopping tenofovir in patients who had a CrCl <50 mL/min while on 
treatment, and Stata 13.0 was used for the statistical analyses.
The University of Cape Town Faculty of Health Sciences Human 
Research Ethics Committee approved the study (576/2011). The 
research ethics committees of the universities of Cape Town and the 
Witwatersrand approved the sites’ contribution of data to the study.
Results
We included 13 168 patients on tenofovir­based first­line ART. Their 
baseline characteristics are shown in Table 1. The most frequently 
prescribed concomitant antiretrovirals were lamivudine (13  003 
patients) and efavirenz (11 641 patients).
Creatinine concentrations were recorded in 11 712 (88.9%) 
patients at baseline, in 9 135/11 657 (78.4%) who were on tenofovir 
at 3 months, in 5 426/10 554 (51.4%) at 6 months, and in 5 949/8 421 
(70.6%) at 12 months. Creatinine concentrations were recorded at 
both baseline and 3 months in 8 406 patients (71.8%) but at all four 
time points in only 1 742 (20.7%) of those followed up for 12 months. 
We were able to calculate CrCl for 79.4% of visits where creatinine 
concentrations were recorded in the database.
Two hundred and twenty­seven (2.2%) of the 10 416 patients who 
had creatinine concentrations recorded at baseline started tenofovir 
despite a CrCl <50 mL/min. Of these 227 patients, 185 had at least 
3  months’ follow­up after starting tenofovir, and tenofovir was 
stopped (within 3 months) in 26 (14.1%). In 119 (81.5%) of the 146 
patients who continued to receive tenofovir and had further creatinine 
concentrations available, the CrCl was ≥50 mL/min at their next visit. 
Among the patients with a CrCl <50 mL/min, the CrCl was ≥50 mL/
min at their following visit in 5 and was stable at their following 
visit in 16, while continuing to receive tenofovir. In 2 patients, CrCl 
deteriorated at their following visit: one stopped tenofovir and the 
CrCl improved to the baseline level, and the other continued to 
receive tenofovir and the CrCl subsequently improved to the baseline 
level. Four patients had no further creatinine concentrations on 
tenofovir available.
A further 525 patients had at least one CrCl <50 mL/min while 
on treatment. Tenofovir was stopped in 114 (29.8%) of the 382 
patients with at least 3 months’ follow up after the low CrCl result. In 
156 (69.0%) of the 226 patients who continued to receive tenofovir 
and had further creatinine concentrations available, the CrCl was 
≥50 mL/min at their next visit. In the patients with a CrCl <50 mL/
min, the CrCl was ≥50 mL/min at their following visit in 21 and was 
<50  mL/min but stable or improving at their following visit in 37, 
while continuing to receive tenofovir. In 2 patients, CrCl deteriorated 
at their following visit: both continued to receive tenofovir and 
CrCl subsequently improved. Ten patients had no further creatinine 
concentrations on tenofovir available.
Logistic regression analysis, adjusting for treatment site, in the 
525 patients who had a CrCl <50 mL/min while on treatment showed 
that clinicians were more likely to stop tenofovir in patients with 
a lower CrCl (odds ratio (OR) 1.14; 95% confidence interval (CI) 
1.02 ­ 1.28 for every 5 mL/min decrease in CrCl), and were also more 
likely to stop in patients with lower CD4 cell counts (OR 1.13; 95% CI 
1.00 ­ 1.29 for every 50 cells/µL decrease in CD4 cell count) (Table 2). 
There were no significant associations between sex, age, concomitant 
antiretrovirals or viral load and stopping tenofovir.
Discussion
We found that clinician compliance with monitoring guidelines was 
good at baseline and reasonable thereafter. Tenofovir was stopped 
only in a minority of patients whose CrCl deteriorated to <50 mL/
min after starting tenofovir. However, CrCl recovered to ≥50 mL/
min in most patients who did not stop tenofovir. Similarly, CrCl 
recovered in most patients who started tenofovir despite a baseline 
CrCl of <50 mL/min.
Data regarding clinician compliance with tenofovir creatinine 
monitoring guidelines are limited. Our findings compare favourably 
with those of Chua et al.,[10] who conducted a retrospective cohort 
analysis in 226 HIV­infected patients in Singapore and found that 
73.5% of patients had creatinine measured at baseline, 84.9% within 
the first 6 months of treatment, 53% at 12 months and 77% at 24 
months. Eighteen patients had a CrCl <50  mL/min after tenofovir 
initiation and tenofovir was stopped because of kidney toxicity in 
2 (11%). In 10 patients CrCl improved despite continuing tenofovir 
without dose adjustment.
Study limitations
Our study has several limitations. We analysed data collected 
for routine clinical practice, and there were missing data. Both 
cohort databases were linked to electronic laboratory records 
to obtain as many creatinine records as possible. However, we 
may have underestimated clinician compliance with monitoring 
guidelines if creatinine was measured but results were not recorded 
in the database. Also, results in the database may not have been 
communicated to clinicians because of clerical errors, so we were 
not able to determine whether or not clinicians who did not stop 
tenofovir in patients with a low CrCl had actually received the 
Table 1. Patient baseline characteristics
Total patients, N 13 168
Males, n (%) 4 923 (37.4%) 
Age (years), median (IQR) 35.5 (30.0 ­ 42.1)
CD4 count (cells/µL), median (IQR)* 166 (83 ­ 239)
Year of ART initiation, n (%)
2010 3 405 (25.8)
2011 4 985 (37.9)
2012 4 778 (36.3)
Follow­up time on tenofovir (months), median (IQR) 14.5 (6.8 ­ 24.1)
IQR = interquartile range.
*Baseline CD4 count was missing in 2 720 patients (20.7%).
Table 2. Associations with stopping tenofovir after  
CrCl <50 mL/min 
Unadjusted Adjusted*
Risk factor n OR 95% CI OR 95% CI
CrCl (/5 mL/min 
decrease)
525 1.03 0.95 ­ 1.12 1.14 1.02 ­ 1.28
CD4 count  
(/50 cells/µL decrease)
388 1.22 1.09 ­ 1.37 1.13 1.00 ­ 1.29
*Adjusted for treatment site and the other variable in the model. 
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abnormal results. Weight data relied solely on manual data entry, 
and there was a high proportion of missing weights. The cohort 
database does not routinely capture adverse drug reaction data, 
and many reasons for stopping drugs were missing, so we cannot 
ascertain accurately whether tenofovir stops were in fact due to 
kidney toxicity.
Conclusions
Our study demonstrates that good compliance with creatinine 
monitoring guidelines is feasible in SA public sector settings with 
reasonable access to laboratory services. The large proportion of 
patients whose renal function improved despite continuing tenofovir 
is reassuring for settings with poor access to laboratory monitoring. 
However, clinicians substituted tenofovir with an alternative NRTI in 
patients with more severe renal impairment and immunosuppression. 
We therefore cannot conclude that it is safe to prescribe tenofovir 
without any creatinine monitoring. Further research is needed to 
inform guidelines regarding how and when best to monitor patients 
on tenofovir, particularly in resource­limited settings.
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